TSS
NBIX icon

Two Sigma Securities’s Neurocrine Biosciences NBIX Stock Holding History

Two Sigma Securities’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-11,991
Closed -$1.51M – 1810
2025
Q2 		$1.51M Buy
+11,991
New +$1.38M 0.19% 124
2024
Q2 		– Sell
-2,380
Closed -$328K – 3420
2024
Q1 		$328K Buy
2,380
+777
+48% +$106K ﹤0.01% 1889
2023
Q4 		$211K Buy
+1,603
New +$185K ﹤0.01% 2354
2023
Q3 		– Sell
-4,839
Closed -$456K – 3291
2023
Q2 		$456K Buy
4,839
+458
+10% +$44.8K 0.01% 1497
2023
Q1 		$443K Buy
4,381
+2,244
+105% +$234K 0.01% 1350
2022
Q4 		$255K Buy
+2,137
New +$250K 0.01% 1696
2022
Q3 		– Sell
-2,773
Closed -$270K – 2918
2022
Q2 		$270K Buy
+2,773
New +$256K 0.01% 1398
2020
Q4 		– Sell
-4,036
Closed -$388K – 1855
2020
Q3 		$388K Buy
+4,036
New +$467K 0.01% 726
2017
Q3 		– Sell
-7,973
Closed -$367K – 1120
2017
Q2 		$367K Buy
+7,973
New +$387K 0.07% 282
2017
Q1 		– Sell
-5,185
Closed -$201K – 1041
2016
Q4 		$201K Buy
5,185
+1,004
+24% +$45.4K 0.07% 454
2016
Q3 		$212K Buy
+4,181
New +$208K 0.07% 424

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Two Sigma Securities's NBIX Position: Q3 2025 in Review

Two Sigma Securities sold out of Neurocrine Biosciences (NBIX) in Q3 2025, closing a stake of 11,991 shares — an estimated $1.51M sold.

Two Sigma Securities first reported a position in NBIX in Q3 2016 and held it in 11 quarters. The position peaked at $1.51M in Q2 2025. 650 funds tracked by Wall St. Rank hold NBIX as of Q3 2025.

  • Two Sigma Securities reported no remaining Neurocrine Biosciences position as of Q3 2025 after selling out during the quarter.
  • Two Sigma Securities sold 11,991 Neurocrine Biosciences shares in Q3 2025, an estimated $1.51M.
  • Two Sigma Securities first reported a position in Neurocrine Biosciences in Q3 2016 and held it in 11 quarters.
  • Two Sigma Securities's Neurocrine Biosciences position peaked at $1.51M in Q2 2025.
  • 650 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2025.

Based on Two Sigma Securities's 13F filing for Q3 2025, filed 14 Nov 2025.